Skip to main content
Figure 5 | Nutrition Journal

Figure 5

From: Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: The pleiotropic effects of folate supplementation

Figure 5

Homocysteine is a competitive inhibitor of PPAR agonists Hcy has recently been found to be a competitive inhibitor of the nuclear transcription factors: Peroxisome proliferator activated receptors (PPARs) alpha and gamma. Hcy acts as a ligand for the PPAR receptors alpha and gamma and therefore competes with the PPAR alpha ligand: ciprofibrate and the PPAR gamma ligand: 15-deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ2). These findings have definite clinical applications, in that; if Hcy is not treated to optimal goals the thiazolidinediones (TZDs) may not have their maximal effect on the PPAR receptor.

Back to article page
\